Efficacy of 2 different fibroblast growth factor receptor-inhibitors in a patient with extrahepatic cholangiocarcinoma harboring an FGFR2 mutation: a case report

Ilianna Galli-Vareia; Petr Szturz; Ioannis A Voutsadakis; Nicolas Villard; Georgia Tsoumakidou; Mapi Fleury; Gabriela Herrera; Francois Fasquelle; Sebastien Godat; Antonia Digklia

doi:10.1093/oncolo/oyae294

Back

Efficacy of 2 different fibroblast growth factor receptor-inhibitors in a patient with extrahepatic cholangiocarcinoma harboring an FGFR2 mutation: a case report

Journal article

Open access

Peer reviewed

Efficacy of 2 different fibroblast growth factor receptor-inhibitors in a patient with extrahepatic cholangiocarcinoma harboring an FGFR2 mutation: a case report

Ilianna Galli-Vareia, Petr Szturz, Ioannis A Voutsadakis, Nicolas Villard, Georgia Tsoumakidou, Mapi Fleury, Gabriela Herrera, Francois Fasquelle, Sebastien Godat and Antonia Digklia

The oncologist (Dayton, Ohio), Vol.30(5), oyae294

05/08/2025

DOI: 10.1093/oncolo/oyae294

PMCID: PMC12060712

PMID: 40338217

Files and links (1)

url

https://doi.org/10.1093/oncolo/oyae294View

Published (Version of record) Open Access

Abstract

Cholangiocarcinoma (CCA) is a type of cancer with few effective systemic therapies. Elucidation of the molecular landscape of the disease from genomic studies based on next-generation sequencing (NGS) has contributed to the introduction of new targeted therapies. One of these treatments consists of a class of small molecules that target members of the fibroblast growth factor receptors (FGFRs) family of receptor tyrosine kinases. We report here on a patient with a cholangiocarcinoma bearing an FGFR2 mutation. The patient was treated with 2 different FGFR inhibitors, as the first caused ocular toxicity. She obtained clinical benefits from both. This case illustrates the efficacy of FGFR inhibitors on cholangiocarcinoma with specific point mutations.

Mutation

Bile Duct Neoplasms - drug therapy

Bile Duct Neoplasms - genetics

Bile Duct Neoplasms - pathology

Cholangiocarcinoma - drug therapy

Cholangiocarcinoma - genetics

Cholangiocarcinoma - pathology

Female

Humans

Middle Aged

Protein Kinase Inhibitors - administration & dosage

Protein Kinase Inhibitors - therapeutic use

Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors

Receptor, Fibroblast Growth Factor, Type 2 - genetics

Details

Title: Subtitle: Efficacy of 2 different fibroblast growth factor receptor-inhibitors in a patient with extrahepatic cholangiocarcinoma harboring an FGFR2 mutation: a case report
Creators: Ilianna Galli-Vareia - University Hospital of Lausanne
Petr Szturz - University Hospital of Lausanne
Ioannis A Voutsadakis - NOSM University
Nicolas Villard - University Hospital of Lausanne
Georgia Tsoumakidou - University Hospital of Lausanne
Mapi Fleury - University Hospital of Lausanne
Gabriela Herrera - University Hospital of Lausanne
Francois Fasquelle - University Hospital of Lausanne
Sebastien Godat - University Hospital of Lausanne
Antonia Digklia - University Hospital of Lausanne
Resource Type: Journal article
Publication Details: The oncologist (Dayton, Ohio), Vol.30(5), oyae294
DOI: 10.1093/oncolo/oyae294
PMID: 40338217
PMCID: PMC12060712
NLM abbreviation: Oncologist
ISSN: 1549-490X
eISSN: 1549-490X
Publisher: OXFORD UNIV PRESS
Language: English
Date published: 05/08/2025
Academic Unit: Internal Medicine
Record Identifier: 9984820531902771

Metrics

44 Record Views